peterschreiber.media Oppenheimer started coverage of Benitec Biopharma (NASDAQ:BNTC) at outperform, citing its gene therapy candidate BB-301 for the treatment of ocular pharyngeal muscular dystrophy,...
Source Linkpeterschreiber.media Oppenheimer started coverage of Benitec Biopharma (NASDAQ:BNTC) at outperform, citing its gene therapy candidate BB-301 for the treatment of ocular pharyngeal muscular dystrophy,...
Source Link
Comments